Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apogee Therapeutics, Inc. - Common Stock
(NQ:
APGE
)
36.37
-2.62 (-6.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
945,649
Open
39.13
Bid (Size)
36.40 (1)
Ask (Size)
36.60 (1)
Prev. Close
38.99
Today's Range
36.26 - 39.33
52wk Range
14.19 - 72.29
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
May 28, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
May 23, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Performance
YTD
+27.57%
+27.57%
1 Month
-30.62%
-30.62%
3 Month
-44.42%
-44.42%
6 Month
+59.10%
+59.10%
1 Year
+71.31%
+71.31%
More News
Read More
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
May 15, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024
May 13, 2024
Via
InvestorPlace
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
May 13, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Earnings Superstars: 3 Stocks Primed to Outperform This Quarter
May 08, 2024
Via
InvestorPlace
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
May 06, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
March 25, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
March 14, 2024
Via
Benzinga
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
March 12, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
March 07, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023
March 05, 2024
Via
InvestorPlace
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
March 05, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Crude Oil Down 1%; Dave Shares Jump After Q4 Results
March 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 05, 2024
Via
Benzinga
Nasdaq Down 250 Points; ISM Services PMI Falls In February
March 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Atopic Dermatitis-Focused Apogee Therapeutics Stock Trading Higher On Tuesday?
March 05, 2024
Via
Benzinga
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
March 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Dips Over 100 Points; Target Posts Upbeat Earnings
March 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 05, 2024
Via
Benzinga
IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome
March 05, 2024
Via
Investor's Business Daily
Topics
Initial Public Offering
Exposures
Securities Market
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of
March 05, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
March 04, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
